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Abstract
Objective: To determine the prognostic value of patient and treatment parameters in osteosarcoma, and whether these are
equally important across international boundaries.
Design: Retrospective, cross-sectional study of 428 patients diagnosed with around-knee osteosarcoma, between 1990 and
1997 in Birmingham, UK, and Bologna, Italy. Disease-free survival (DFS) and overall survival (OS) assessed by Kaplan–
Meier, Fisher’s PLSD and Cox proportional hazard regression.
Results: Five-year DFS and OS were 56 and 73% at Centre 1, compared to 43 and 60% at Centre 2 (P¼0.0022 and
P¼0.025, respectively). The most important bad prognostic factors for DFS and OS respectively were raised alkaline
phosphatase at diagnosis (P¼0.002 and P¼0.003), tumour necrosis <90% following chemotherapy (P¼0.001 and
P¼0.004) and volume >150 cm
3 at diagnosis (P¼0.04 and P¼0.006). The most significant combination of bad prognostic
factors was alkaline phosphatase and tumour necrosis. A total of 73% of patients at Centre 1 had greater than 90% necrosis
of the tumour following neoadjuvant chemotherapy compared with 29% at Centre 2.
Conclusions: Tumour-based prognostic factors have similar significance across international boundaries. Chemotherapy
effectiveness appears to be a major factor in explaining the survival difference between the two centres.
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Introduction
Chemotherapy has dramatically changed the prog-
nosis for patients with osteosarcoma. The optimum
regime has yet to be determined and few randomised
clinical trials have helped clarify the problem, often
showing little difference in outcome between
regimes.
1–6
A large number of clinical studies have attempted
to identify the prognostic factors that influence
survival in osteosarcoma. However, variation in
methodology has led to inconsistent results and
difficulty in interpreting the true prognostic effect
of many of the variables evaluated.
7–13 In any case,
most of the prognosticators reported lack specificity
as pre-treatment predictive factors, thus preventing
their use as a basis for a more differentiated algo-
rithm of risk-adapted chemotherapeutic and surgical
intervention. Furthermore, few studies have looked
at whether these prognostic factors are equally
pertinent in different therapeutic and geographical
populations. This paper therefore attempts to iden-
tify the importance of some of the prognosticators
already reported in the literature and whether they
hold equal value at two specialist orthopaedic
oncology centres from different countries.
A second factor was trying to identify whether
there was any evidence for a perceived difference in
survival between patients treated at the two centres
and to find potential reasons for this.
Methods
The two centres used for this study are both large
centres of musculoskeletal oncology and both main-
tain prospective databases of patients treated, their
treatment and outcome. Both centres agreed that
their blinded data could be collected and used for
this study without wishing to identify specifically
which centre was which. Hence the centres will
hereafter be identified as Centre 1 and Centre 2.
A computer database search was used to identify
all patients under the age of 40 who were diagnosed
with conventional high grade osteosarcoma localised
to the distal femur or proximal tibia between 1990
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skip lesions or metastatic disease at diagnosis were
excluded.
Individual patient records were traced where
possible. The patient and treatment parameters
recorded are listed in Table 1. A total of nine
different chemotherapy regimes were used between
the two centres. Comparisons between these regimes
were outside the remit of this study and have already
been published elsewhere.
1,14–16 Hence, we merely
compared chemotherapy at centre 1 with that used
at centre 2.
The data were analysed using the ‘Statview’
statistical analysis program with respect to disease-
free survival (DFS) (time in weeks to developing
metastatic disease and/or local recurrence) and
overall survival (OS) (time in weeks to death from
date of diagnosis).
2 All data were analysed using
Kaplan–Meier survival analyses with the exception of
excision margins and histological subtype which were
analysed using Fisher’s PLSD ANOVA post-hoc
test. Survival curves, generated by Kaplan–Meier
analysis, were compared with the log rank test and
significance was set at P<0.05. Significant param-
eters were further analysed using the Cox pro-
portional hazards model for multivariate analysis.
Hazard ratios have been calculated using a propor-
tional hazards method with only the noted covariate
in the model. Chi-squared and P values generated
were used to denote co-variation.
Results
Population demographics
The study population comprised 428 patients, 265
patients from centre 1 and 163 from centre 2. There
was a male preponderance with a gender ratio of
1.4:1 and the average age at diagnosis was 15.8 years.
There were 271 tumours of the distal femur and
157 of the proximal tibia. The mean duration of
symptoms prior to diagnosis was 14 weeks (median
8 weeks). Twenty-one patients had a pathological
fracture. The mean diameter of the tumours was
10cm and the volume was 239ml. Table 1 lists the
factors studied and Table 2 shows the proportion of
patients with different factors at each centre.
Treatment variables
All patients underwent attempts at curative treat-
ment with chemotherapy and surgery. The margins
of excision were documented in 411 patients and
were intralesional in 15, marginal in 54, wide in 324
and radical in 18 (this only arose following amputa-
tion). Adequate margins were those found to be wide
or radical. The percentage necrosis following neoad-
juvant chemotherapy was available for 377 patients.
Of these, 211 had a good response with >90%
necrosis, whilst 166 had a poor response with <90%.
Table 2. Variation in patient and treatment factors between the two centres
Centre 1 Centre 2 Significance
Patient factors
Mean age 15.2 16.1 NS
Mean duration of symptoms (weeks) 11 19 0.01
Sex ratio F/M 105/160 75/88 NS
Pathological fracture 10/265 (3.7%) 11/163 (6.7%) NS
Raised alkaline phosphatase at diagnosis 99/230 (43%) 66/120 (55%) 0.03
Tibia/femur ratio 94/171 63/100 NS
Mean volume (ml) 224 275 NS
Treatment factors
Mean percent necrosis 89% 62% <0.0001
Proportion with >90% necrosis 169/232 (73%) 42/145 (29%) <0.0001
Proportion with inadequate margins 19/259 (7%) 50/152 (33%) <0.0001
Table 1. Patient and treatment parameters recorded
Specialist centre at which treatment received
Patient gender
Age at diagnosis
Date of diagnosis
Symptom duration
History of trauma
Presence of pathological fracture at diagnosis
Serum alkaline phosphatase level at diagnosis
Tumour volume (cm
3)*
Chemotherapy regime employed
Surgical technique
Histological subtype
Percentage chemotherapy induced necrosis
Enneking Stage at diagnosis
Tumour margins
Date of last follow-up
Status at last follow-up (dead, dead from a non-correlated
cause, alive and disease free, alive with metastases,
alive with local recurrence, alive with metastatic
disease and local recurrence)
Time from diagnosis to death/metastatic disease/local
recurrence
*Volume was calculated by using the formulas: A B C 0.52
for spherical tumours and A B C 0.735 for elliptical
tumours, where A, B and C are the three dimensions of the
tumour.
14 S. Ford et al.Differences between the two centres are shown in
Table 2.
Local control
Thirty-two patients developed a local recurrence. It
arose in 24 of the 271 patients with distal femoral
lesions (8.8%) and eight of the 156 with proximal
tibial lesions (5.1%). Local recurrence was strongly
related to margins of excision and effectiveness of
chemotherapy. (Table 3)
Patient survival
Patients treated at Centre 2 were less successful in
terms of DFS and OS. Five-year DFS was 56% in
centre 1 and 43% in centre 2 (P¼0.0022) (Fig. 1).
Five-year OS was 73%(CI 3%) in centre 1 and
60% (CI 4%) in centre 2 (P¼0.025) (Fig. 2). The
effect of chemotherapy necrosis on survival at the
different centres is similar but patients with poor
necrosis at Centre 2 (5-year OS 57%) did a lot worse
than those at Centre 1 (5-year OS 62%) (Fig. 3).
Prognostic factors
Tables 4 and 5 list patient and treatment parameters
investigated by survival analysis with hazard ratios
and confidence intervals generated using the Mantel
Cox test.
Tumour volume greater than 150cm
3, percentage
chemotherapy induced necrosis less than 90%, and
raised alkaline phosphatase at diagnosis are strongly
significant for an association with less favourable
DFS and OS. Gender, site, duration of symptoms,
history of trauma, surgical stage, adequacy of surgical
margins and presence of a pathological fracture
at diagnosis were all shown to have no correlation
with DFS or OS. There was no particular histo-
logical subtype shown to have any influence on OS.
Table 4. Details of factors affecting disease-free survival on
univariate and multivariate analysis. A high hazard ratio
implies an increased risk to overall survival in the presence of
that factor, a lower ratio (<1) implies a risk less than unity
Hazard
ratio
95% CI P
value
Factor
Symptoms <8 weeks 0.94 0.70–1.26 0.68
Age <16 1.26 0.95–1.66 0.10
Size <10cm 0.56 0.35–0.89 0.014
Raised alkaline
phosphatase
1.61 1.19–2.19 0.002
Volume >150ml 1.51 1.02–2.2 0.042
Site: femur 1.05 0.79–1.39 0.73
Pathological fracture: 0.78 0.39–1.59 0.49
Sex: female 0.96 0.73–1.27 0.78
Necrosis <90% 1.62 1.21–2.17 0.0013
Centre 2 1.54 1.17–2.02 0.0022
Adequate surgical margins 0.73 0.51–1.05 0.088
On multivariate analysis the following remained significant:
Necrosis <90% 1.624 1.185–2.226 0.0026
Raised alkaline phosphatase 1.502 1.094–2.060 0.0117
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Fig. 1. Kaplan–Meier analysis comparing DFS time for
Centre 1 and Centre 2. Mantel–Cox P¼0.0022.
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Fig. 2. Kaplan–Meier analysis comparing OS for Centre 1
and Centre 2. Mantel–Cox P¼0.025.
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Fig. 3. Kaplan–Meier analysis comparing overall survival for
patients at Centres 1 and 2 split by percent necrosis.
Table 3. Showing the incidence of local recurrence in relation
to both margins of excision and effectiveness of chemotherapy
<90% necrosis >90% necrosis
Intralesional or
marginal margin
7/37 (19%) 3/19 (17%)
Wide or radical margin 13/121 (11%) 4/187 (2%)
Comparison of conventional treatment 15Centre of treatment has a weak association with
improved survival.
Multivariate analysis using the Cox model
Factors found to be prognostically significant on
univariate testing were systematically combined in
an attempt to generate the highest total chi-squared
value with all prognostic factors still reaching sig-
nificance, this was deemed the combination of
prognostic factors which best explains DFS and OS.
The combination found to best explains DFS and
OS is alkaline phosphatase level at diagnosis and
degree of chemotherapy induced necrosis (Tables 4
and 5).
Discussion
The aim of this paper has been to determine the
prognostic value of patient and treatment param-
eters in osteosarcoma and whether these are equally
important across international boundaries. Secondly,
to try and identify if there is a difference in outcome
for patients with osteosarcoma between two centres
and, if so, why? We have used prognostic factors
previously found to be important and which could
be readily collected from each centre.
9 We have
specifically restricted this survey to tumours of the
distal femur or proximal tibia as all authors agree that
these two sites have similar outcomes.
Local recurrence is generally accepted to be a poor
prognostic indicator.
18,19 We have confirmed it’s
relationship to both margins of excision and to
effectiveness of chemotherapy. If either of these are
unsatisfactory then the risks of local recurrence
increase.
20–22 Like others, we have been unable to
show a demonstrable and independent effect of
LR on overall survival when analysed using multi-
factorial methods.
Age and gender
Gender is not significantly correlated with adverse
outcome. A male preponderance and average age at
diagnosis of 15.8 years are consistent with data from
other centres.
7
Enneking stage at diagnosis
Tumour stage holds no significance for DFS or OS.
Lack of survival significance between stages could
indicate that confinement within or invasion beyond
the cortex has no prognostic significance; however, a
lack of discriminating power of this classification may
play a role in masking any trend.
23
Histological subtype
We were unable to confirm a recent report that
histological subtype has any prognostic value.
24
Confounding factors in the analysis included inher-
ent observer bias and small numbers of certain
subtypes limiting statistical power.
Anatomical site
Location of the tumour, be it distal femur or
proximal tibia, has no bearing on DFS or OS.
Similarly, a number of other authors have not found
anatomical site to be a significant predictor of disease
outcome.
12,14
Tumour volume and size
Tumours >150cm
3 are highly significant for a
reduced DFS and OS lending status as a major
prognostic factor in the pre-treatment assessment of
new patients. Furthermore, tumour volume when
considered as a continuous variable using the Cox
model, remains significant for OS per unit increase
in volume. Tumour size (maximum length) was not
found to be useful in predicting OS or DFS.
Symptom duration
We found greater symptom duration to be inversely
correlated with DFS, with little influence on OS.
Others have found the reverse or no association with
a favourable outcome.
25 Sources of bias in this
observation include symptom duration not being
recorded for all patients and an element of recall bias
on behalf of the patient.
Table 5. Details of factors affecting overall survival on
univariate and multivatiate analysis. A high hazard ratio
implies an increased risk to overall survival in the presence of
that factor, a lower ratio (<1) implies a risk less than unity
Hazard
ratio
95% CI P
value
Factor
Symptoms <8 weeks 1.06 0.74–1.53 0.74
Age <16 1.11 0.784–1.57 0.56
Size <10cm 0.65 0.36–1.15 0.14
Raised alkaline
phosphatase
1.62 1.23–2.69 0.0027
Volume >150ml 2.08 1.23–3.5 0.0057
Site: femur 1.07 0.75–1.53 0.71
Pathological fracture: 0.933 0.41–2.12 0.87
Sex: female 0.904 0.64–1.28 0.57
Necrosis <90% 1.746 1.19–2.56 0.0044
Centre 1 0.67 0.474–0.952 0.025
Adequate surgical
margins
0.78 0.49–1.23 0.28
No local recurrence 0.54 0.32–0.94 0.029
On multivariate analysis the following remained significant:
Necrosis <90% 1.815 1.20–2.74 0.0044
Raised alkaline
phosphatase
1.66 1.09–2.51 0.0165
16 S. Ford et al.Alkaline phosphatase
A raised serum alkaline phosphatase at diagnosis is
highly correlated with shorter DFS and OS.
Interestingly serum alkaline phosphatase given as
normal or raised does not carry the same degree of
significance for a shorter DFS or OS in centre 2 as
that demonstrated in centre 1. This may be because
the mean percentage necrosis for centre 2 is
significantly lower than that for centre 1 with the
strong correlation between percentage necrosis and
DFS and OS partially masking the contribution of
alkaline phosphatase as a determinator of disease
recurrence and poor survival. Furthermore when
tumour volume and alkaline phosphatase are ana-
lysed simultaneously by multivariate analysis, P
values rise and chi-squared values drop indicating a
degree of co-variation between tumour volume and
raised alkaline phosphatase. A possible explanation
would be that tumours capable of producing alkaline
phosphatase manufacture increasingly larger quan-
tities as the tumour burden increases. This would be
consistent with reports that alkaline phosphatase is
more likely to be elevated in those presenting with
metastatic disease.
11 However, tumours that do not
produce alkaline phosphatase may be just as
advanced as those that do. An alkaline phospha-
tase-producing tumour could be more aggressive,
with a relative resistance to chemotherapy induced
necrosis. However, this is unlikely as we could find
no correlation between alkaline phosphatase and
percentage necrosis in the Cox model.
Degree of necrosis
Degree of chemotherapy induced necrosis has long
been recognised as the most important predictor
of subsequent outcome for localised extremity
disease.
26 A greater degree of necrosis incurs a
more favourable outcome. Micrometastases from
therapeutically sensitive primaries are logically less
likely to remain viable than those of resistant lesions.
Percentage necrosis is significantly greater in
centre 1 than centre 2 and has greater significance
in centre 2 for predicting adverse outcome. Could
percentage necrosis account for the survival discre-
pancy between the centres? The observation that 73%
of patients in Centre 1 appear to have a good response
to chemotherapy compared with just 29% in Centre 2
probably goes a long way to explaining the survival
difference between the two centres. However, even
patients with a good response at Centre 2 do not do as
well as those at Centre 1 (Fig. 3) and the reason for
this is not clear from this study. One possible reason
for the difference in degree of chemotherapy-induced
necrosis is a difference in histopathological inter-
pretation between the centres. This is unlikely to
explain such a large difference as the pathologists at
both centres adhere to well established international
criteria for assessing tumour response.
27 Another
possibility is that the surgical intervention took
place at different times, i.e., the patients had more
neoadjuvant chemotherapy at centre 1 than at centre
2. The range of times to definitive surgery were,
however, not significantly different between the two
centres. We believe that the difference between the
two chemotherapy regimes employed at the two
centres offers the most likely explanation for the
differences in chemotherapy necrosis.
Chemotherapy regimes
The chemotherapy regimes used at the two centres
differed significantly in that the regimes used at
Centre 1 involved three- or four-drug regimes
(involving a combination of doxorubicin, cisplatin,
methotrexate and ifosfamide), whilst the majority of
patients at Centre 2 usually had a two-drug regime
(principally doxorubicinþcisplatin). A total of 73%
of patients at Centre 1 had a good (>90% necrosis)
result compared with only 29% at centre 2. This
difference is dramatic and would appear to indicate
the supremacy of a multidrug regime although
previous randomised studies have failed to show
this.
1 We cannot exclude, however, the possibility
that some other factor such as dose intensity may be
responsible for this difference although we feel this is
not likely.
It is interesting to note that a good response is as
effective in both centres; that is to say, if the tumour
is sensitive to the chemotherapeutic agents then, after
a period of 300 weeks, appearance of metastatic
disease or local recurrence is highly unlikely. In
addition, this also shows that the follow-up policy
and subsequent imaging techniques used are equally
effective in both centres. There is no reason to
suggest that centre 1 is more effective at picking up
metastatic disease in the pre-treatment setting creat-
ing a falsely effective treatment technique when
compared to centre 2 as both centres used similar
staging techniques with CT chest and bone scans
prior to treatment.
A poor response to initial chemotherapy led to a
detrimental effect on patient survival at both centres,
but the effect was more apparent at Centre 2. The
reasons for this were not investigated as part of this
study. It is possible that second line chemotherapy
may ‘rescue’ more patients at Centre 1 than at
Centre 2.
Our study identifies tumour volume, percentage
chemotherapy-induced necrosis and alkaline phos-
phatase as major patient prognostic indicators for
DFS and OS. A combination of raised alkaline
phosphatase and poor chemotherapy induced necro-
sis are the most accurate predictors of poor DFS
and OS. The predictive powers of individual prog-
nosticators hold different values in each cohort.
Chemotherapy regime used in each centre is
a potential major factor in explaining apparent
Comparison of conventional treatment 17survival differences in patients treated for conven-
tional osteosarcoma. However, this is a retrospective
study and a large randomised prospective study
could help resolve these issues. In any case, the rarity
of these tumours makes continued international
co-operation between specialist centres essential if
we are to maximise treatment potential.
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